Condition: Obesity · Muscle Loss · Sponsor: Actimed Therapeutics Ltd
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).
This description comes directly from the study's public registry record.
Fabio Dorigotti, MD · +41 79 653 55 67 · info@actimedtherapeutics.com
Always discuss trial participation with your own doctor first.
| Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje' | Belgrade, Serbia | Recruiting |
| Clinical Hospital Center Bezanijska kosa | Belgrade, Serbia | Recruiting |
| University Clinical Center of Serbia | Belgrade, Serbia | Recruiting |
| University Clinical Center Kragujevac | Kragujevac, Serbia | Recruiting |
| Klinika Za Endocrinologiju, Dijabetes I Bolesti Metabolizma | Niš, Serbia | Recruiting |
| University Clinical Center of Vojvodina | Novi Sad, Serbia | Recruiting |
| Opsta bolnica Pancevo | Pančevo, Serbia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07101939